Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.

By F. Mahon, D. Réa, J. Guilhot, F. Guilhot, F. Huguet, F. Nicolini, L. Legros, A. Charbonnier, A. Guerci, B. Varet and 3 more. The Lancet Oncology, 2010

1,525 citations recorded by the source corpus.

Subfields: Genetics, Hematology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/858b7f8ee3a9f8dc15f635ccf7dce5481a73ee5d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Brian J. Druker
2. J. Cortes
3. Andreas Hochhaus
4. H. Kantarjian
5. M. Baccarani

In Hematology

1. Brian J. Druker
2. J. Cortes
3. J. Goldman
4. J. Apperley
5. Andreas Hochhaus
6. H. Kantarjian
7. M. Baccarani

In Rheumatology

1. Brian J. Druker
2. J. Cortes
3. Andreas Hochhaus
4. H. Kantarjian
5. M. Baccarani

Citations in the corpus

• Chronic Myeloid Leukemia (2007, positive): “Several prospective studies have suggested that patients with sustained complete molecular response (CMR; defined as molecular relapse [MR] >4.5 ) may be able to stop imatinib treatment 101,102 .”
• European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. (2013, background): “There have been controlled attempts to discontinue imatinib in some patients who were in sustained, deep MR (MR or better).(126-129) Approximately 40% of them maintained the same degree of response, with a follow-up of 1 to 4 years.”